Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 6/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22043172 | 0.92 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL25990480 | 0.86 | GNAO1 (0.51) | SMN1; SMN2ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL4196163 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1DRD2SLC6A4L3MBTL1 | |
| SCHEMBL1160925 | 0.85 | KMT2A (0.51) | SMN1; SMN2GNAI3GNAO1GNAI1KMT2A | |
| SCHEMBL23135123 | 0.85 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1KMT2ADRD2SLC6A4 | |
| SCHEMBL25959922 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1KMT2ADRD2SLC6A4 | |
| SCHEMBL18951862 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1L3MBTL1HRH3 | |
| SCHEMBL26042815 | 0.83 | L3MBTL1 (0.40) | ALDH1A1GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL24802125 | 0.82 | ALOX15 (0.46) | GNAI3GNAO1GNAI1KMT2AKDM4E | |
| SCHEMBL23269619 | 0.81 | KMT2A (0.51) | SMN1; SMN2ALDH1A1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024132278-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389223-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | SMN1; SMN2 4590/4885ALDH1A1 3281/4885GNAI3 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.